Tag: fcx

Fibrocell Announces Closing of $18 Million Private Placement

EXTON, Pa., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today reported the receipt of $18.1 million of gross proceeds from the sale of convertible promissory notes and warrants in its previously announced private placement financing. Fibrocell intends to use the proceeds of the financing for the continued pre-clinical and clinical development of…

Fibrocell Announces Proposed Public Offering of Common Stock and Warrants

EXTON, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) (Fibrocell) today announced that it intends to offer and sell shares of its common stock and related warrants to purchase shares of its common stock in an underwritten public offering.  The shares of common stock and related warrants will be immediately separable and…

Fibrocell Reports Second Quarter 2016 Financial Results and Recent Operational Highlights

EXTON, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today reported financial results for the second quarter ended June 30, 2016 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT. “Fibrocell is advancing into the second half of 2016 focused on innovative gene-therapy programs…

Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

EXTON, Pa., July 27, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that the first two adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). FCX-007 is Fibrocell’s orphan gene-therapy product candidate for the treatment of RDEB, a devastating, painful, blistering…

Fibrocell Expects Significant Cost Savings from Wind-Down of azficel-T Operations

EXTON, Pa., June 29, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) today announced significant cost savings are expected from the wind-down of its azficel-T operations and that the Company is focusing its efforts and resources on its gene therapy portfolio of product candidates that are developed in conjunction with Intrexon Corporation—FCX-007 for the treatment…
News – @Fibrocell #Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

- Phase I/II Clinical Trial to Begin in Second Quarter of 2016 - EXTON, Pa. and GERMANTOWN, Md., April 18, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases affecting the skin, connective tissue and joints, and Intrexon Corporation (NYSE:XON), a leader…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Freeport-McMoRan Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 28, 2016 – FCX

NEW YORK, March 23, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Freeport-McMoRan Inc. (“Freeport-McMoRan”) (NYSE:FCX) between February 27, 2015 and January 15, 2016. You are hereby notified that a securities class action lawsuit has been…

Fibrocell Reports Fourth Quarter and Full Year 2015 Financial Results and Operational Highlights

EXTON, Pa., March 10, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases affecting the skin, connective tissue and joints, today reported financial results for the fourth quarter and year ended December 31, 2015 and operational highlights. Fibrocell will host a conference…

News $FCX #FreeportMcMoRan – Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Freeport-McMoRan Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – FCX

STEVENSON, Md., Feb. 08, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of purchasers of Freeport-McMoRan, Inc. (NYSE:FCX) (“Freeport” or the “Company”) securities during the period…

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Freeport-McMoRan Inc. and a Lead Plaintiff Deadline of March 28, 2016 – FCX

NEW YORK, Feb. 01, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Arizona on behalf of investors who purchased Freeport-McMoRan Inc. (NYSE:FCX) securities between February 27, 2015 and January 15, 2016. Click here to learn about the…

Fibrocell Science Reports Third Quarter 2015 Financial Results and Operational Highlights

- Company to Host Conference Call and Webcast, Today at 8:30 a.m. EST - EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for rare and serious skin and connective tissue diseases, today reported financial results for the quarter ended…

Fibrocell and Intrexon Provide Regulatory Update for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

EXTON, Pa. and GERMANTOWN, Md., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today provided an update on the…
Top Five Gold Stocks Breaking-Out: $SWC $ASM $FCX $GOLD $NEM
Top Gold Stocks